Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
News
Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time
First-of-its-kind technology stack in autoimmune diseases.
Provides unprecedented insights into optimal patient treatment pathway.
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
– Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine
– Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Led by new investor Petrichor, with participation from new and existing investors
Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved therapies
Top-line data expected in mid-2023 from Phase 3 pivotal study evaluating QTORIN™ rapamycin in Pachyonychia Congenita
Venatorx Pharmaceuticals Announces Organizational Changes
Chief Medical Officer Timothy Henkel, M.D., Ph.D., Retires
Vincent Milano Steps Down from Board of Directors
Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test
The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo’s Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder
Preclinical Data Demonstrates MEB–1170 Lacks Adverse Effects of Opioids Including Respiratory Depression and Opioid Abuse Potential